Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kalos

Showing results (171-180 of 236) with videos related to

Pageof 24
Sort By:
Cancer Immunology Research|September 26, 2014
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanomaDavid L Bajor, Xiaowei Xu, Drew A Torigian, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
European Journal of Internal Medicine|October 23, 2023
One-year outcomes following a hypertensive urgency or emergencyChristos Fragoulis, Dimitrios Polyzos, Andreas Mavroudis, et al.
Clinical and Experimental Pharmacology & Physiology|March 1, 2018
Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up studyIoannis Andrikou, Costas Tsioufis, Kyriakos Dimitriadis, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLCHilal Ozakinci, Bina Desai, Denise Kalos, et al.
Translational Lung Cancer Research|May 22, 2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumorsHilal Ozakinci, Bina Desai, Denise Kalos, et al.
European Journal of Preventive Cardiology|October 31, 2021
Profile and management of hypertensive urgencies and emergencies in the emergency cardiology department of a tertiary hospital: a 12-month registryChristos Fragoulis, Kyriakos Dimitriadis, Eirini Siafi, et al.
The Journal of Experimental Medicine|June 5, 2002
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector functionClaes Ohlén, Michael Kalos, Laurence E Cheng, et al.
Blood|April 12, 2015
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patientsMichael A Pulsipher, Chris Carlson, Bryan Langholz, et al.
Cancer Immunology Research|March 1, 2014
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignanciesGregory L Beatty, Andrew R Haas, Marcela V Maus, et al.
Pageof 24

Showing results (171-180 of 236) with videos related to

Sort By:
Pageof 24
Cancer Immunology Research|September 26, 2014
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanomaDavid L Bajor, Xiaowei Xu, Drew A Torigian, et al.
Cancer Immunology, Immunotherapy : CII|August 28, 2007
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki, Katherine S Panageas, Leah Ben-Porat, et al.
European Journal of Internal Medicine|October 23, 2023
One-year outcomes following a hypertensive urgency or emergencyChristos Fragoulis, Dimitrios Polyzos, Andreas Mavroudis, et al.
Clinical and Experimental Pharmacology & Physiology|March 1, 2018
Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up studyIoannis Andrikou, Costas Tsioufis, Kyriakos Dimitriadis, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLCHilal Ozakinci, Bina Desai, Denise Kalos, et al.
Translational Lung Cancer Research|May 22, 2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumorsHilal Ozakinci, Bina Desai, Denise Kalos, et al.
European Journal of Preventive Cardiology|October 31, 2021
Profile and management of hypertensive urgencies and emergencies in the emergency cardiology department of a tertiary hospital: a 12-month registryChristos Fragoulis, Kyriakos Dimitriadis, Eirini Siafi, et al.
The Journal of Experimental Medicine|June 5, 2002
CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector functionClaes Ohlén, Michael Kalos, Laurence E Cheng, et al.
Blood|April 12, 2015
IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patientsMichael A Pulsipher, Chris Carlson, Bryan Langholz, et al.
Cancer Immunology Research|March 1, 2014
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignanciesGregory L Beatty, Andrew R Haas, Marcela V Maus, et al.
Pageof 24